Provided by Tiger Trade Technology Pte. Ltd.

Cue Biopharma, Inc.

25.87
+0.36001.41%
Post-market: 25.870.00000.00%19:30 EDT
Volume:228.12K
Turnover:5.95M
Market Cap:187.93M
PE:-0.88
High:27.43
Open:25.89
Low:24.88
Close:25.51
52wk High:45.50
52wk Low:4.97
Shares:7.26M
Float Shares:6.85M
Volume Ratio:0.64
T/O Rate:3.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.4600
EPS(LYR):-8.4244
ROE:-1603.48%
ROA:-172.66%
PB:81.35
PE(LYR):-3.07

Loading ...

B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff

TIPRANKS
·
Sep 22

Top Midday Decliners

MT Newswires Live
·
Sep 22

Cue Biopharma Shares Reverse Premarket Gains; Last Down 3.3%

THOMSON REUTERS
·
Sep 21

Cue Biopharma Reports Phase 2 CSU Trial Meets Primary Endpoint for Anti-IgE Drug CUE-221

Reuters
·
Sep 21

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Reuters
·
Sep 21

Top Premarket Gainers

MT Newswires Live
·
Sep 21

Cue Biopharma Shares Jump with Positive Results in Chronic Spontaneous Urticaria Trial

Dow Jones
·
Sep 21

Cue Biopharma Surges After Positive Results from Mid-Stage Study for CUE-221

Reuters
·
Sep 21

Cue Biopharma Shares Jump 48.2% Premarket After Positive Results from Mid-Stage Study for Cue-221 in Hives Treatment

THOMSON REUTERS
·
Sep 21

Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate

MT Newswires Live
·
Sep 21

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

TIPRANKS
·
Sep 20

Cue Biopharma Says CUE-221 Phase 2 Trial in Chronic Spontaneous Urticaria Meets Primary Endpoint

Reuters
·
Sep 20

Cue Biopharma Announces Positive Topline Results from Cue-221 Phase 2 Study in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
Sep 20

Cue Biopharma, - Phase 2 Primary and Key Secondary Endpoints Met

THOMSON REUTERS
·
Sep 20

B. Riley Initiates Cue Biopharma With Buy Rating, $83 Price Target

MT Newswires Live
·
Sep 18

Cue Biopharma Initiated at Buy by B. Riley Securities

Dow Jones
·
Sep 18

U.S. Research Roundup-Amrize, Carmax, VF Corp

Reuters
·
Sep 18

Cue Biopharma, Inc. : Jefferies Adjusts Target Price to $66 from $4 to Reflect Reverse Stock Split

THOMSON REUTERS
·
Aug 28

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Reuters
·
Aug 28

Adial Pharmaceuticals Posts Bigger-than-Expected Q2 Net Loss, Hurt by Acquisition Charges

Reuters
·
Aug 17